<DOC>
	<DOCNO>NCT01000779</DOCNO>
	<brief_summary>Background : Variceal bleed major cause morbidity mortality patient Non Cirrhotic Portal Hypertension ( NCPH ) . Beta blocker ( BB ) endoscopic variceal ligation ( EVL ) use prevent rebleeding patient , largely base data cirrhotic patient . Endotherapy form EST well study prevent rebleed patient NCPH . Initial study show EST significantly reduce rebleeding rate patient NCPH . Data study suggest rebleed rate approximately 25 % 2yr 35 % 5 year . Beta blocker find quite effective primary well secondary prophylaxis variceal bleed cirrhotic accepted mode treatment . In contrast liver cirrhosis , publish data effect beta blocker therapy NCPH scanty . Animal data human data suggest beta blocker reduce portal pressure patient NCPH . In two placebo control trial propranolol secondary prophylaxis variceal bleed non cirrhotic patient . study demonstrate efficacy propranolol decrease rebleed rate . However , comparison hae make EVL till date . Hypothesis : The investigator hypothesis In patient NCPH , treatment beta blocker lead reduction portal pressure decrease portosystemic shunt lead reduction variceal rebleeding Aim study : Aim : To compare efficacy safety Propranolol EVL prevention variceal rebleeding patient NCPH .</brief_summary>
	<brief_title>Comparison Endoscopic Variceal Ligation ( EVL ) With Propranolol Non Cirrhotic Portal Hypertension ( NCPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Patients Non Cirrhotic Portal Hypertension ( NCPH ) present Liver Diseases Followup Clinic history hemetemesis and/or malena within past 6 week proven esophageal varix bleed source upper GI endoscopy A history surgery portal hypertension Patients already EST , EVL , glue injection program presenting hospital Patients already beta blocker primary prophylaxis variceal bleed Severe cardiopulmonary renal disease Bradycardia ( basal heart rate , &lt; 50 beat per minute [ bpm ] ) complete heart block A history severe side effect contraindication Î² blocker , like bronchial asthma , diabetes mellitus , heart failure , peripheral vascular disease , prostatic hypertrophy , arterial hypotension ( systolic blood pressure &lt; 90 mm Hg ) Refusal give inform write consent participate trial Patients bleed gastric varix Portal Hypertensive Gastropathy ( PHG ) . Patients failure primary hemostasis acute bleed also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Non Cirrhotic Portal Hypertension , secondary prophylaxis</keyword>
</DOC>